Dyax Corp. (NASDAQ:DYAX)
| CAPS Rating |
|
|---|---|
| Open | $1.48 |
| Previous Close | $1.49 |
| Daily Range | $1.38 - $1.49 |
| 52-Week Range | $1.10 - $2.33 |
| Market Cap | $141.21M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 245,221 |
| Average Daily Volume | 0 |
DYAX
VS S&P 500 (SPY)
How do you think DYAX will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
DYAX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
DYAX News and Commentary
- PDL BioPharma’s Management Is Creating Value – The Motley Fool
- Shire Enters a Crowded Market – The Motley Fool
- Shire Records a Win and Loss in Same Week – Minyanville
- PDL BioPharma's Management Is Creating Value – The Motley Fool
- Low-Priced Biotech Stocks With Insider Buying – SeekingAlpha
- FDA Kicks Dust on Alimera's Fairy Tale – The Motley Fool
- Dyax Corporation CEO Discusses Q3 2010 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- Dyax Corporation CEO Discusses Q3 2010 Results - Earnings Call Transcript – SeekingAlpha
- Dyax Corp. Q2 2010 Earnings Call Transcript – SeekingAlpha Transcripts
- Dyax Corp. Q2 2010 Earnings Call Transcript – SeekingAlpha
- UPDATE 1-Dyax posts narrower-than-expected Q4 loss – Reuters
- 3 Stocks in a Tailspin – The Motley Fool
- Buy a Company, Get the Plant for Free – The Motley Fool
- I Love This Industry – The Motley Fool
- DYAX Out! – Blog at The Motley Fool
- UPDATE 1-Dyax shrs soar after FDA approves genetic-disorder drug – Reuters
- FDA OKs Dyax Drug For Rare Swelling Disorder; Stock Soars – SmartMoney
- UPDATE 1-Dyax gets FDA marketing nod on genetic disease drug – Reuters
- 10 Stocks Shaking the Market – The Motley Fool
- DYAX is the Ticket! – Blog at The Motley Fool
RSS Headlines
Fool UK
